Compass Pathways CEO on Trump's Order to Expand Psychedelics Research
لماذا يهم
التحليل معروض بالإنجليزية · الترجمة العربية قيد الإعداد
FinBERT analysis of financial text showing neutral sentiment with 94.1% confidence.
نبرة المقال
التأثير المتوقع على السوق
مسار الأدلة
الأدلة
مصدر التحليل بالذكاء الاصطناعي
المعرّفات التقنية
- وسم المزوّد
- huggingface-ProsusAI/finbert
- إصدار التحليل
- huggingface-ProsusAI/finbert
- معرّف المقال
- 73519
المصدر الأصلي
Shares of companies involved in psychedelic-tied therapies surged Monday after President Donald Trump signed an executive order to expedite research and access. US-traded shares of Compass Pathways spiked as much as 53% while AtaiBeckley surged by 37%. GH Research jumped 34% and Definium Therapeutics rallied 16%. The AdvisorShares Psychedelics ETF (PSIL) also climbed as much as 20% — touching its highest intraday level since July 2023. The new order directs the US Food and Drug Administration to issue expedited review vouchers to psychedelics with a so-called breakthrough designation, shortening the review time to one to two months from six to ten months. AtaiBeckley, Definium and Compass Pathways all have therapies with breakthrough status. Compass Pathways CEO Kabir Nath joins Bloomberg Businessweek Daily to discuss. He speaks with Carol Massar and Tim Stenovec. (Source: Bloomberg)
اقرأ المقال كاملاً على Bloomberg
المقال الأصلي منشور بواسطة Bloomberg في إبريل 21, 2026. التحليل والرؤى المقدمة من AnalystMarkets AI.